FDA Advisory Committee Approval of First Biosimilar Leaves Questions Unanswered: Sandoz's Filgrastim Faces Naming and Court Hurdles.
نویسنده
چکیده
As first biosimilar approval nears, key questions remain.
منابع مشابه
Biologics as countermeasures for acute radiation syndrome: where are we now?
Despite significant scientific advances toward the development of a safe, nontoxic and effective radiation countermeasure for acute radiation syndrome (ARS) over the past six decades, no drug has been approved by the US FDA. Several biologics are currently under development as radiation countermeasures for ARS, of which three have received FDA Investigational New Drug (IND) status for clinical ...
متن کاملZarxio (Filgrastim-sndz): The First Biosimilar Approved by the FDA.
Zarxio (filgrastim-sndz), a biosimilar for the treatment of severe chronic neutropenia.
متن کاملBiosimilar Naming Conventions: Pharmacist Perceptions and Impact on Confidence in Dispensing Biologics.
BACKGROUND The approval of the first biosimilar in the United States has placed increased pressure on the FDA to provide guidance on the naming convention that will be assigned to current and future biosimilars. The release of the FDA draft guidance on nonproprietary naming of biosimilars in August 2015 established a naming convention for all biologic products, including biosimilars. However, t...
متن کاملRevisiting financial conflicts of interest in FDA advisory committees.
CONTEXT The Food and Drug Administration (FDA) Safety and Innovation Act has recently relaxed conflict-of-interest rules for FDA advisory committee members, but concerns remain about the influence of members' financial relationships on the FDA's drug approval process. Using a large newly available data set, this study carefully examined the relationship between the financial interests of FDA Ce...
متن کاملUtilizing data consortia to monitor safety and effectiveness of biosimilars and their innovator products.
BACKGROUND The Biologics Price Competition and Innovation Act, introduced as part of the Affordable Care Act, directed the FDA to create an approval pathway for biologic products shown to be biosimilar or interchangeable with an FDA-approved innovator drug. These biosimilars will not be chemically identical to the reference agent. Investigational studies conducted with biosimilar agents will li...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- P & T : a peer-reviewed journal for formulary management
دوره 40 3 شماره
صفحات -
تاریخ انتشار 2015